Imaging test for people receiving cancer immunotherapy
Part of Cancer clinical trials.
This study tests a new imaging agent that may help doctors see how well immunotherapy is working in your body. It is for people with advanced cancer who are already planned to receive checkpoint inhibitor drugs or tebentafusp-tebn for uveal melanoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced cancer that has spread, and you are about to start a checkpoint inhibitor drug (like PD-1, PD-L1, CTLA-4, or LAG-3 inhibitors) or have uveal melanoma and are getting tebentafusp-tebn.
- You have at least one tumor that is 15 mm or larger (or two tumors both 15 mm or larger) that can be seen on a CT or MRI scan.
- You are able to care for yourself and are up and about more than 50% of your waking hours (ECOG 0-2).
- You are expected to live more than 6 months.
- You are willing to have a biopsy of one of your tumors if needed, and you have tissue from a recent biopsy or surgery (within 90 days) available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that helps find cancer cells that have come back. It is given as an injection and then a scan is done to see if it helps doctors locate the cancer.
This study tests a new imaging method to see if a special 'tracer' can light up tumors that have a protein called PD-L1, which is a target for immunotherapy. By taking a PET scan, doctors hope to predict whether immunotherapy will work for you.
This study tests a new imaging agent that helps PET scans show cancer more clearly. It may help doctors see where cancer is in your body and plan your treatment better.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This study tests a new imaging agent (a special dye) that might help doctors see tumors more clearly in people with certain advanced cancers. You would receive the dye and then have scans to see if it highlights cancer areas.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.